Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $6.2300 (-4.74%) ($5.9300 - $6.7400) on Fri. Oct. 26, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.29% (three month average) | RSI | 4 | Latest Price | $6.2300(-4.74%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -11.7% a day on average for past five trading days. | Weekly Trend | ADAP declines -25.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(19%) GDXJ(13%) JETS(13%) ICLN(12%) TAN(12%) | Factors Impacting ADAP price | ADAP will decline at least -2.645% in a week (0% probabilities). VIXM(-10%) XLP(-8%) VXX(-6%) XLV(-4%) TBT(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.645% (StdDev 5.29%) | Hourly BBV | 0 () | Intraday Trend | -5.9% | | | |
|
1 - 5 Day Possible Target | $-28.57(-558.59%) | Resistance Level | $11.07 | 5 Day Moving Average | $6.77(-7.98%) | 10 Day Moving Average | $8.96(-30.47%) | 20 Day Moving Average | $11.07(-43.72%) | To recent high | -56% | To recent low | 0% | Market Cap | $963m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |